Table 1 Demographic and clinicopathological parameters of high and low CXCL5 expression group patients with GBM
From: Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion
Characteristic | Low expression of CXCL5 | High expression of CXCL5 | P |
|---|---|---|---|
N | 84 | 84 | |
T stage, n (%) | 0.091 | ||
T1 | 46 | 44 | |
T2 | 23 | 25 | |
T3 | 10 | 9 | |
T4 | 5 | 6 | |
N stage, n (%) | 0.668 | ||
N0 | 79 | 80 | |
N1 | 5 | 4 | |
M stage, n (%) | 0.774 | ||
M0 | 81 | 79 | |
M1 | 3 | 5 | |
Pathologic stage, n (%) | 0.189 | ||
Stage I | 48 | 48 | |
Stage II | 21 | 23 | |
Stage III | 9 | 7 | |
Stage IV | 6 | 6 | |
Gender, n (%) | 0.598 | ||
Female | 42 | 40 | |
Male | 42 | 44 | |
OS event, n (%) | 0.014 | ||
Alive | 52 | 40 | |
Dead | 32 | 44 | |
Vascular invasion, n (%) | 0.077 | ||
No | 61 | 58 | |
Yes | 23 | 26 | |
Histologic grade, n (%) | 0.801 | ||
G1 | 23 | 20 | |
G2 | 48 | 49 | |
G3 | 11 | 12 | |
G4 | 2 | 3 | |
Age, median (IQR) | 65.8 (51, 66) | 66.1 (50, 73) | 0.401 |
AFP(ng/ml), median (IQR) | 8.3 (4, 108.5) | 25.86 (9,804.75) | < 0.01 |
BMI, median (IQR) | 26.24 (22.37, 28.47) | 22.56 (19.36, 31.01) | 0.029 |